

Llorenç Caballeria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6219024/publications.pdf>

Version: 2024-02-01

60
papers

4,827
citations

172207

29
h-index

110170

64
g-index

71
all docs

71
docs citations

71
times ranked

4046
citing authors

#	ARTICLE	IF	CITATIONS
1	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	2.4	80
2	Risk of Liver Fibrosis According to TSH Levels in Euthyroid Subjects. <i>Journal of Clinical Medicine</i> , 2021, 10, 1350.	1.0	4
3	Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study. <i>European Journal of Endocrinology</i> , 2021, 184, 587-596.	1.9	12
4	TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. <i>Journal of Clinical Medicine</i> , 2021, 10, 2907.	1.0	12
5	Relaci3n entre el hipotiroidismo y el h3gado graso no alcoh3lico en una poblaci3n espa±ola. <i>Medicina Cl3nica</i> , 2020, 154, 1-6.	0.3	13
6	Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population. <i>Medicina Cl3nica (English Edition)</i> , 2020, 154, 1-6.	0.1	9
7	Recomendaciones para la detecci3n, diagn3stico y seguimiento de los pacientes con enfermedad por h3gado graso no alcoh3lico en atenci3n primaria y hospitalaria. <i>Medicina Cl3nica</i> , 2019, 153, 169-177.	0.3	18
8	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	1.8	104
9	Prevalence of Early Chronic Kidney Disease and Main Associated Factors in Spanish Population: Populational Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1384.	1.0	3
10	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Cl3nica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
11	Documento de consenso. Manejo de la enfermedad hep3tica grasa no alcoh3lica (EHGNA). Gu3a de pr3ctica cl3nica. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2018, 41, 328-349.	0.2	71
12	High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1138-1145.e5.	2.4	180
13	Markers of hepatic fibrosis. <i>Medicina Cl3nica (English Edition)</i> , 2018, 150, 310-316.	0.1	5
14	Marcadores de fibrosis hep3tica. <i>Medicina Cl3nica</i> , 2018, 150, 310-316.	0.3	12
15	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterolog3a Y Hepatolog3a (English Edition)</i> , 2018, 41, 328-349.	0.0	7
16	Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. <i>PLoS ONE</i> , 2018, 13, e0198327.	1.1	38
17	Screening studies of transient elastography and FibroTest in the general population – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246-247.	3.7	0
18	Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. <i>American Journal of Gastroenterology</i> , 2017, 112, 114-119.	0.2	34

#	ARTICLE	IF	CITATIONS
19	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	3.7	131
20	Acceptability and quality of abdominal ultrasound studies requested by medical professionals. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2016, 39, 516-525.	0.0	1
21	Nonalcoholic steatohepatitis and diabetes. <i>Endocrinología Y Nutrición (English Edition)</i> , 2016, 63, 377-379.	0.5	5
22	Esteatohepatitis no alcohólica y diabetes. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2016, 63, 377-379.	0.8	5
23	Alerts in electronic medical records to promote a colorectal cancer screening programme: a cluster randomised controlled trial in primary care. <i>British Journal of General Practice</i> , 2016, 66, e483-e490.	0.7	30
24	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
25	Non-alcoholic fatty liver disease. Role of primary care physicians. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 112-114.	0.1	0
26	Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 254-262.	2.9	19
27	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
28	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
29	Estrategias para la detección de infección por virus de la hepatitis C en población general. <i>Revista Clínica Española</i> , 2014, 214, 242-246.	0.2	6
30	Strategies for the detection of hepatitis C viral infection in the general population. <i>Revista Clínica Española</i> , 2014, 214, 242-246.	0.3	4
31	Using Transient Elastography to Detect Chronic Liver Diseases in a Primary Care Nurse Consultancy. <i>Nursing Research</i> , 2013, 62, 450-454.	0.8	21
32	Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1007-1011.	0.8	24
33	Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. <i>Autoimmunity Highlights</i> , 2012, 3, 105-112.	3.9	7
34	Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 24-32.	0.8	196
35	Reply.. <i>Hepatology</i> , 2010, 52, 2239-2239.	3.6	1
36	Adequacy and quality of abdominal echographies requested by primary care professionals. <i>BMC Gastroenterology</i> , 2010, 10, 101.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis. <i>Gastroenterology</i> , 2010, 138, 2348-2356.	0.6	115
38	New ELISA for Detecting Primary Biliary Cirrhosisâ€“Specific Antimitochondrial Antibodies. <i>Clinical Chemistry</i> , 2009, 55, 978-985.	1.5	71
39	Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. <i>Hepatology</i> , 2009, 50, 1162-1168.	3.6	93
40	High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 347-354.	1.3	19
41	Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. <i>BMC Gastroenterology</i> , 2008, 8, 44.	0.8	17
42	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. <i>Hepatology</i> , 2007, 45, 1583-1583.	3.6	51
43	Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. <i>BMC Gastroenterology</i> , 2007, 7, 41.	0.8	35
44	Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2006, 130, 715-720.	0.6	649
45	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 573-577.	1.8	163
46	Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1105-1110.	0.2	111
47	Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2004, 22, 353-362.	3.0	64
48	Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , 2003, 98, 2268-2274.	0.2	24
49	Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. <i>Hepatology</i> , 2002, 35, 652-657.	3.6	77
50	Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virusâ€“related cirrhosis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1160-1163.	0.2	26
51	Collagen type Î±1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. <i>Hepatology</i> , 2001, 33, 554-560.	3.6	64
52	Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence To That in Hepatitis C Virusâ€“Related Cirrhosis. <i>American Journal of Gastroenterology</i> , 2001, 96, 1160-1163.	0.2	96
53	Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. <i>Journal of Hepatology</i> , 2000, 32, 561-566.	1.8	254
54	HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. <i>Tissue Antigens</i> , 1999, 53, 459-469.	1.0	151

#	ARTICLE	IF	CITATIONS
55	S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. <i>Journal of Hepatology</i> , 1999, 30, 1081-1089.	1.8	428
56	Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. <i>Journal of Hepatology</i> , 1998, 28, 54-60.	1.8	68
57	Carbohydrate-Deficient Transferrin as a Marker of Alcohol Consumption in Male Patients with Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 923-927.	1.4	23
58	Zinc Administration Improves Gastric Alcohol Dehydrogenase Activity and First-Pass Metabolism of Ethanol in Alcohol-Fed Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 1997, 21, 1619-1622.	1.4	9
59	Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. <i>Hepatology</i> , 1996, 24, 1399-1403.	3.6	27
60	Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury. <i>Hepatology</i> , 1990, 12, 1295-1299.	3.6	242